Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus IM2 for Relapsed/Refractory T-LBL/T-ALL
NCT05576532Phase 2Unknown
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in T-cell lymphoblastic lymphoma (T-LBL), T-cell acute lymphoblastic leukemia (T-ALL), sponsored by Shanghai General Hospital. Status: unknown.
02
Drugs
venetoclax
03
Conditions
T-cell lymphoblastic lymphoma (T-LBL)T-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT05576532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576532.